What is the 52 Week High and Low of Global Health Share Price?

The 52 week high and low prices of Global Health share price is 1456.5 & 956. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Global Health Share price

Q: How to buy Global Health Share at Choice?

To buy Global Health stocks , log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Global Health, choose your preferred order type, and place the trade.

MEDANTA

Healthcare Large Cap

1242.5

30.60 (2.52%)

NSE

BSE

Last updated on 15 May, 2026 | 15:56 IST

BUYSELL

Today's High

1278.00

Today's Low

1220.90

52 Week Low

956.00

52 Week High

1456.50

Free Demat with Zero AMC*

Global Health Chart

ChartIQ

TradingView

Global Health Share Key Metrics

Volume

7.81 L

Market Cap

33397.20 CR

LTQ@LTP

100@1242.50

ATP

1254.33

Var Margin

16.25 %

Circuit Range

969.6-1454.2

Delivery %

63.15 %

Value

97.91 CR

ASM/GSM

No

Market Lot

1

Summary

Global Health share price is ₹1242.5 as of 16 May, 2026. The stock Global Health intraday movement has stayed between ₹1220.90 and ₹1278.00, while on a 52-week basis,Global Health price 52 week high is ₹1456.50 & its 52 week low is ₹956.00.

In terms of trading activity, Global Health has recorded a volume of 780605 shares, The Global Health has a market cap of ₹268790382 CR. The stock’s Average Traded Price (ATP) stands at ₹1254.33, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 100 @ ₹1242.50.

Global Health operates within a circuit range of ₹969.60 – ₹1454.20, with a Value of ₹97.91 CR. The Delivery Percentage for the day is 63.15%. Additionally, Global Health currently falls under the No framework, and trades with a market lot size of 1.

Global Health Fundamentals

P/E Ratio

60.02

P/B Ratio

8.42

Div. Yield

0.04

Sector P/E

56.28

Sector P/B

-15.69

Sec. Div. Yield

1.98

Global Health Resistance and Support

Pivot 1216.03

Resistance

First Resistance

1237.66

Second Resistance

1263.43

Third Resistance

1285.06

Support

First Support

1190.26

Second Support

1168.63

Third Support

1142.86

Global Health Shareholding Pattern

2022-23
2023-24
2024-25
2025-26
2026-27

Total Promoters

Segment

Percent

Total Promoters

33.01%

Mutual Fund

13.91%

Insurance

0.62%

Foreign Institutional Investors

10.15%

Domestic Institutional Investors

0.23%

Retail

42.08%

Others

0%

Total Promoters

MAR '26

33.01%

Global Health Corporate Actions

Date	Agenda
2026-05-14	Audited Results & Final Dividend
2026-02-04	Quarterly Results
2025-11-07	Quarterly Results
2025-08-07	Quarterly Results
2025-05-15	Audited Results & Final Dividend
2025-02-04	Quarterly Results

Global Health News

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

Global Health has provided a link to the audio recording of its earnings conference call held on May 15, 2026. The call, hosted by ICICI Securities, discussed the company's financial results for Q4 FY26 and the full financial year.

May 15 2026 16:05:00

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

Global Health announced strong Q4 FY26 results with total income increasing 25.3% YoY to Rs.11,958 million. Net profit for the quarter grew 39.7% YoY to Rs.1,417 million, driven by robust operational performance and patient volume growth.

May 14 2026 18:05:00

Global Health Limited

Global Health's board has declared a final dividend of Rs.0.50 per equity share for the financial year 2025-26. This dividend is equivalent to 25% of the face value. The record date will be announced closer to the Annual General Meeting date.

May 14 2026 17:05:00

Global Health Ltd - 543654 - Announcement under Regulation 30 (LODR)-Change in Management

Global Health announced key leadership changes. Kedar Ashok Apte has been appointed as Chief Marketing & Growth Officer, and Jagdeep Singh as General Counsel and Senior Management Personnel, both effective May 14, 2026. This strengthens the company's strategic leadership.

May 14 2026 17:05:00

Global Health Ltd - 543654 - Board Meeting Outcome for Board Meeting Outcome For Intimation Under Regulation 30 Of SEBI Listing Regulations.

Global Health Limited reported Q4 FY26 consolidated revenue of ₹11,590.47 mn and net profit of ₹1,416.53 mn, up 45% and 40% YoY respectively. The company also recommended a final dividend of ₹0.50 per equity share and appointed two Senior Management Personnel (SMPs).

May 14 2026 16:05:00

Global Health Ltd - 543654 - Board Meeting Intimation for Approval Of Audited Financial Results Of The Company For The Quarter And Financial Year Ended March 31, 2026 And Recommendation Of Final Dividend.

Global Health's Board of Directors is scheduled to meet on May 14, 2026. The agenda includes considering and approving the audited financial results for the quarter and year ended March 31, 2026, and recommending a final dividend.

May 06 2026 15:05:00

Global Health Limited

Medanta will acquire an 80-bed Cancer Hospital in Indore from Asian Institute of Oncology for ₹30 crores, expanding its oncology program. This acquisition strengthens its presence in Central India and is expected to drive operational synergies.

Apr 27 2026 15:04:00

Global Health Limited

Global Health acquired a 79-bedded cancer care hospital business in Indore from Asian Institute of Oncology Private Limited for a cash consideration of ₹30 crores. This acquisition will expand the Medanta network and is expected to complete by September 30, 2026, subject to regulatory approvals.

Apr 27 2026 14:04:00

Global Health Limited

Global Health (Medanta) board approved the acquisition of a 79-bedded cancer care hospital in Indore for ₹30 crores cash. This strategic move strengthens the company's oncology services and regional presence.

Apr 27 2026 14:04:00

Global Health Limited

Global Health (Medanta) board approved the acquisition of a 79-bedded cancer care hospital in Indore for ₹30 crores cash. This strategic move strengthens the company's oncology services and regional presence.

Apr 27 2026 14:04:00

NSE : 11956

BSE : 543654

ISIN : INE474Q01031

Our Company was incorporated as ‘Global Health Private Limited’ on August 13 2004 at New Delhi India as a private limited company under the Companies Act 1956 pursuant to a certificate of incorporation by the RoC. Our Company was then converted into a public limited company under the Companies Act 2013 pursuant to a special resolution passed by our Shareholders in the EGM held on July 31 2021 and consequently the name of our Company was changed to ‘Global Health Limited’ and a fresh certificate of incorporation dated August 11 2021 was issued by the RoC.Milestones:2009Gurugram hospital was established2011-Received the NABH accreditation for Gurugram hospital-Received the NABL accreditation for Gurugram hospital2013-Carlyle (i.e. Investor Selling Shareholder) invested in our Company-1st Joint Commission International (“JCI”) accreditation for the hospital at Gurugram2014-Received the NABH (blood bank) accreditation for Gurugram hospital-Entered into a 27-year lease for hospital at Indore2015-Temasek invested in our Company-Entered into a 15-year lease for hospital at Ranchi-Our subsidiary GHPPL entered into a 33-year concession agreement with Governor of Bihar for the development operation and maintenance of a proposed hospital on public-private partnership at Patna2016-Received the NABH accreditation for Indore hospital-Entered into a 90-year lease for our hospital at Noida (which is under construction)2018Received the NABH accreditation for Ranchi hospital2019Commencement of operations of new hospital at Lucknow2020-Patna hospital’s outpatient department facility launched-Gurugram hospital outpatient department pharmacy taken in-house-Received the Research Ethics NABH accreditation2021-Lucknow hospital outpatient department pharmacy taken in-house-Indore hospital outpatient department pharmacy taken in-house-Ranchi hospital outpatient department pharmacy taken in-house-Launch of outpatient department pharmacy at south Delhi clinic2022-Patna hospital’s inpatient department facility commenced operations-Received the NABH accreditation for Lucknow hospital-Launch of Patna hospital outpatient department pharmacy

Name	Position
Rahul Ranjan	Company Secretary & Compliance Officer
Naresh Trehan	Chairman & Managing Director

Global Health Similar Stocks

Ajanta Pharma Ltd.

3177.20

-82.00 (2.52%)

Ipca Laboratories Ltd.

1605.00

21.10 (1.33%)

Aster DM Healthcare Ltd.

753.65

7.05 (0.94%)

Narayana Hrudayalaya Ltd.

1841.10

21.70 (1.19%)

JB Chemicals & Pharmaceuticals Ltd.

2140.40

2.60 (0.12%)

Emcure Pharmaceuticals Ltd.

1704.90

29.20 (1.74%)

Krishna Institute of Medical Sciences Ltd

761.65

-11.65 (1.51%)

Gland Pharma Ltd.

1868.30

-29.90 (1.58%)

Dr. Lal Pathlabs Ltd.

1602.90

2.80 (0.17%)

Wockhardt Ltd.

1545.90

-1.30 (0.08%)

Global Health FAQs

The Buying Price of Global Health share is 1242.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Global Health stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Global Health, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Global Health shares is 60.02. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Global Health shares is 8.42. Useful to assess the stock's value relative to its book value.

To assess Global Health’s valuation compare Sector P/E, P/B which are 56.28 & -15.69 with sector averages, along with growth rates and financial metrics.

The Market Cap of Global Health is 33397.20 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Global Health share price is 1456.50 & 956.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Global Health belongs to the Healthcare sector.